Comparing inhaled isopropyl alcohol and eucalyptus for migraine-related nausea
Double Blind Randomized Control Trial of Inhaled Isopropyl Alcohol Vapors Versus Inhaled Eucalyptus Scent for the Treatment of Nausea Associated With Acute Migraine
This study is testing whether inhaling isopropyl alcohol can help reduce nausea during migraine attacks better than inhaling eucalyptus scent, which is being used as a comparison.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | HonorHealth Research Institute Academic / other |
| Locations | 1 site (Scottsdale, Arizona) |
| Trial ID | NCT05175521 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness and side effects of inhaled isopropyl alcohol vapor (IAV) compared to inhaled eucalyptus scent (IES) in reducing nausea associated with acute migraine attacks. Utilizing a double-blind randomized control design, the study will measure nausea reduction and the time until patients require additional anti-nausea medications. The eucalyptus scent is used as a placebo since it has not demonstrated efficacy for this condition.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 who experience nausea associated with migraines at least twice a month.
Not a fit: Patients under 18 or over 65 years old, or those without a diagnosis of acute migraine, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new, effective treatment option for patients suffering from nausea during migraine attacks.
How similar studies have performed: While the use of inhaled isopropyl alcohol for nausea is not widely studied, similar approaches using aromatherapy have shown mixed results, making this a potentially novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients 18 to 65 years old with nausea associated migraines at least twice per month Exclusion Criteria: * Patients \<18 or \>65 years old * Patients without a diagnosis of acute migraine
Where this trial is running
Scottsdale, Arizona
- HonorHealth Bob Bové Neuroscience Institute — Scottsdale, Arizona, United States (Recruiting)
Study contacts
- Principal investigator: Jill Rau, MD, PhD — HonorHealth Research Institute
- Study coordinator: Angelina Cooper
- Email: ancooper@honorhealth.com
- Phone: 480-583-3193
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.